Key clinical point: Results of a cohort study provide additional evidence that continued use of tumor necrosis factor inhibitors or methotrexate is acceptable in most patients who acquire COVID-19.
Major finding: The likelihood of hospitalization or death was not statistically different between COVID-19 patients exposed or not exposed to those drugs, with risk ratios of 0.91 and 0.87, respectively.
Study details: A study of a global research network database including 32,076 patients with COVID-19, including 214 with recent exposure to tumor necrosis factor inhibitors or methotrexate.
Disclosures: Authors reported no conflicts of interest and no funding sources related to the study.
Zinn Z et al. J Am Acad Dermatol. 2020 Sep 11. doi: 10.1016/j.jaad.2020.09.009.